Anyone have thoughts on this paragraph from the announcement, i didnt think much of it at first, just that it is working, but this seems to at face value be surprising on the upside hence further evaluation....
"Specific instances of markedly improved behaviours (i.e. reduction in fear, agitation and anxiety) are being
further investigated to fully assess and understand the positive neuro-psychological impact of NTI164
treatment in these patients. This research along with further data assessment from the Trial will be
completed in Q2. These key areas of neuro-behavioural change will be the key focus of the upcoming drug
registration trials due to commence in Q3 calendar 2022."
I wonder if anxiety is covered by the licencing (it is neurological)?
Ann: Successful Landmark Study in Paediatric ASD, page-18
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
